Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254254 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT00254254: Completed Phase 2 study of Type 2 Diabetes Mellitus, sponsored by AstraZeneca.
NCT00254254 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by AstraZeneca. The registered enrollment target is 13 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00254254, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological effects (pharmacodynamics), and tolerability of exenatide in these subjects.
Primary Outcome
To assess pharmacokinetics of exenatide by measuring peak plasma time, time to peak concentration, terminal elimination half-life, apparent elimination time constant, apparent clearance, apparent volume of distribution, and area under concentration curve.
Conditions Studied
Interventions
- DRUG Exenatide - Exenatide - Placebo
- DRUG Exenatide - Placebo - Exenatide
- DRUG Placebo - Exenatide - Exenatide
Study Locations (5)
Arkansas
- Research Site - Little Rock
California
- Research Site - San Diego
Colorado
- Research Site - Denver
Kentucky
- Research Site - Louisville
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00254254 record still lists
NCT00254254 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Exenatide - Exenatide - Placebo is the first listed.
NCT00254254 lists 5 locations in 5 states (Arkansas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT00254254 about?
NCT00254254 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus". This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological effects (pharmacodynamics), and tolerability of exenatide in these subjects.
What is the current status of trial NCT00254254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-02. Estimated completion is 2007-02.
What conditions does trial NCT00254254 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00254254?
The interventions under investigation include: Exenatide - Exenatide - Placebo (DRUG), Exenatide - Placebo - Exenatide (DRUG), Placebo - Exenatide - Exenatide (DRUG).
Who is sponsoring clinical trial NCT00254254?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00254254 being conducted?
This trial has 5 study locations across Arkansas, California, Colorado, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00254254's enrollment target sits among peer trials
13 124th of 130 higher than 7 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia